Login to Your Account



Genentech's Avastin Receives Approval In Colorectal Cancer

By Brady Huggett and Aaron Lorenzo


Friday, February 27, 2004
Genentech Inc.'s Avastin received FDA approval as a first-line treatment in metastatic colorectal cancer. With the company saying it will launch the product into the eager arms of patients and doctors within three days and sales expectations high, the drug seems bound for biotechnology folklore. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription